Phase Ib/II study of BL-8040 in combination with Atezolizumab in patients with pancreatic cancer

Trial Profile

Phase Ib/II study of BL-8040 in combination with Atezolizumab in patients with pancreatic cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Atezolizumab (Primary) ; BL 8040 (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 08 Aug 2017 This trial is part of MORPHEUS, Roche's Novel Cancer Immunotherapy Development Platform, according to a BioLineRx media release.
    • 10 Jul 2017 Status changed from planning to recruitingn according to a BioLineRx media release.
    • 01 Jun 2017 According to a BioLineRx media release, Genentech has filed regulatory submissions required to commence this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top